To test the hypothesis that a 4 week treatment with atomoxetine is more effective than placebo in patients with combined type Attention Deficit/Hyperactivity Disorder (ADHD), patients with only Reading Disorder, and patients with combined type ADHD and Reading Disorder.

Phase 1

• Conditions: Attention-Deficit/Hyperactivity Disorder (AD/HD); MedDRA version: 23.0Level: LLTClassification code 10003735Term: Attention deficit-hyperactivity disorderSystem Organ Class: 100000004873; Therapeutic area: Diseases [C] - Nervous System Diseases [C10]

• Registration Number: EUCTR2006-001866-18-Outside-EU/EEA
• Lead Sponsor: Eli Lilly and Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-12-02
• Last Update Posted: 6 December 2021

Recruitment & Eligibility

• Status: A
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1) Clinical diagnosis with Attention Deficit Hyperactivity Disorder and/or Reading Disorder.
Are the trial subjects under 18? yes
Number of subjects for this age range: 121
F.1.2 Adults (18-64 years) no
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1) Patients with Conduct Disorder
2) Patients who have a history of Bipolar I or II Disorder, psychosis, or Pervasive Development Disorder.
3) Patients who have a current diagnosis of Vocal Tic Disorder, Obsessive Compulsive Disorder, Major Depressive Disorder, Post Traumatic Stress Disorder, Anxiety Disorder, and certain other learning disorders.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified